InsiderTrades

Form 4 for EOG EOG Resources

Accepted 2022-05-24 00:00:00 ET · period of report 2022-05-23 · accession 0001127602-22-015446 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-05-24 2022-05-23 EOG Helms Lloyd W Jr Pres, COO D - Sale to Iss $126.62 -15.7K 140.9K -10% -$1.99M
DM 2022-05-24 2022-05-23 EOG Helms Lloyd W Jr Pres, COO F - Tax $126.62 -1,996 139.9K -1% -$252.7K
DM 2022-05-24 2022-05-23 EOG Helms Lloyd W Jr Pres, COO M - OptEx $95.70 +20.8K 148.2K +16% +$1.99M
DM 2022-05-24 2022-05-23 EOG Helms Lloyd W Jr Pres, COO M - OptEx $0.00 -20.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-05-23 D D 8,328 $126.62 142,518.94 D — —
2 Common Common Stock 2022-05-23 F D 1,032 $126.62 141,486.94 D — —
3 Common Common Stock 2022-05-23 M A 10,950 $96.29 150,846.94 D — —
4 Common Common Stock 2022-05-23 F D 964 $126.62 139,896.94 D — —
5 Common Common Stock 2022-05-23 D D 7,376 $126.62 140,860.94 D — —
6 Common Common Stock 2022-05-23 M A 9,825 $95.05 148,236.94 D — —
7 Derivative Stock Appreciation Rights 2022-05-23 M D 9,825 $0.00 0 D $95.05 · 2017-09-29 to 2023-09-29 9,825 Common Stock (F1) The SARs granted became exercisable in 25% increments beginning one year from the September 29, 2016 date of grant and on each of the next three grant date anniversaries. The SARs granted became fully exercisable on September 29, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock.
8 Derivative Stock Appreciation Rights 2022-05-23 M D 10,950 $0.00 0 D $96.29 · 2018-09-25 to 2024-09-25 10,950 Common Stock (F2) The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 25, 2017 date of grant. The SARs granted became fully exercisable on September 25, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock.